Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 799-805

  Tseng, Jeng Sen ^a,b   Yang, Tsung Ying ^b   Chen, Kun Chieh ^a,b   Hsu, Kuo Hsuan ^a,c   Yu, Chong Jen ^d   Liao, Wei Yu ^a,c   Tsai, Chi Ren ^b,e   Tsai, Meen Hsin ^d,f   Yu, Sung Liang ^d,g   Su, Kang Yi ^a   Chen, Jeremy J W ^e   Chen, Hsuan Yu ^a   Chang, Gee Chen ^a,b,c,h,i  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b Taichung General Veterans Hospital   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

ⁱ NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Epidermal growth factor receptor mutation; Epidermal growth factor receptor tyrosine kinase inhibitor; Non small cell lung cancer; Pemetrexed

Indexed keywords

AFATINIB; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PEMETREXED; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CONTROL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; EGFR GENE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER TOXICITY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTANT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TAIWAN; TREATMENT OUTCOME;

EID: 84901409645     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S62639     Document Type: Article

References (27)

1. West H, Harpole D, Travis W. Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. Chest. 2009;136(4):1112-1118.
2. Moreira AL, Thornton RH. Personalized medicine for non-small-cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testing. Clin Lung Cancer. 2012;13(5): 334-339.
3. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-2388.
4. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121-128.
5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10): 947-957.
6. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735-742.
7. Mok T, Yang JJ, Lam KC. Treating patients with EGFR-sensitizing mutations: first line or second line-is there a difference? J Clin Oncol. 2013;31(8):1081-1088.
8. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543-3551.
9. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327-3334.
10. Leighl NB. Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol. 2012;19 Suppl 1:S52-S58.
11. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res. 2011;17(17):5530-5537.
12. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC Cancer Staging Handbook. 7th ed. New York: Springer; 2009.
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
14. Tseng JS, Yang TY, Chen KC, Hsu KH, Chen HY, Chang GC. Retrospective study of erlotinib in patients with advanced squamous lung cancer. Lung Cancer. 2012;77(1):128-133.
15. An SJ, Chen ZH, Su J, et al. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PloS One. 2012;7(6):e40109.
16. Wu SG, Yang CH, Yu CJ, et al. Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer. 2011;72(3):333-339.
17. Camidge DR, Kono SA, Lu X, et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol. 2011;6(4):774-780.
18. Kim YH, Hirabayashi M, Togashi Y, et al. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902. Cancer Chemother Pharmacol. 2012;70(2):271-276.
19. Gridelli C, Ciardiello F, Gallo C, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol. 2012;30(24):3002-3011.
20. Wu JY, Shih JY, Yang CH, et al. Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer. Int J Cancer. 2010;126(1):247-255.
21. Chang GC, Tsai CM, Chen KC, et al. Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients. J Thorac Oncol. 2006;1(6):520-525.
22. Bai H, Wang Z, Chen K, et al. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol. 2012;30(25):3077-3083.
23. Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol. 2010;21(12):2324-2332.
24. Deng QF, Su B, Zhao YM, Zhou CC. [Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs]. Zhonghua Zhong Liu Za Zhi. 2008;30(11):813-816. Chinese.
25. Sun JM, Oh DY, Lee SH, et al. The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. Lung Cancer. 2010;68(3):427-432.
26. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011;17(11):3812-3821.
27. Christoph DC, Asuncion BR, Hassan B, et al. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. J Thorac Oncol. 2013;8(1):19-30.